Wei Lu

Xgene Pharmaceutical, Inc. is a venture capital-backed company based in an international location. Xgene Pharmaceutical utilizes their proprietary linker technology to create novel, multimodal, conjugated molecules for the treatment of neurological disorders. The Chinese company's focus is on improving the efficacy and tolerability of pain therapeutics by addressing the complexity of any given disease. Healthcare professionals frequently prescribe more than one therapeutic agent, each with a different mode of action, and multi-modal therapy has demonstrated improved outcomes across a range of conditions. Xgene Pharmaceutical provides a link to better therapies. The company was founded in 2015 by Jing Hong Xu and Feng Xu, with Jing Hong Xu serving as the CEO since then.

Xgene Pharmaceutical, Inc. is a venture capital-backed company based in an international location. Xgene Pharmaceutical utilizes their proprietary linker technology to create novel, multimodal, conjugated molecules for the treatment of neurological disorders. The Chinese company's focus is on improving the efficacy and tolerability of pain therapeutics by addressing the complexity of any given disease. Healthcare professionals frequently prescribe more than one therapeutic agent, each with a different mode of action, and multi-modal therapy has demonstrated improved outcomes across a range of conditions. Xgene Pharmaceutical provides a link to better therapies. The company was founded in 2015 by Jing Hong Xu and Feng Xu, with Jing Hong Xu serving as the CEO since then.

Xgene Pharmaceutical, Inc. is a venture capital-backed company based in an international location. Xgene Pharmaceutical utilizes their proprietary linker technology to create novel, multimodal, conjugated molecules for the treatment of neurological disorders. The Chinese company's focus is on improving the efficacy and tolerability of pain therapeutics by addressing the complexity of any given disease. Healthcare professionals frequently prescribe more than one therapeutic agent, each with a different mode of action, and multi-modal therapy has demonstrated improved outcomes across a range of conditions. Xgene Pharmaceutical provides a link to better therapies. The company was founded in 2015 by Jing Hong Xu and Feng Xu, with Jing Hong Xu serving as the CEO since then.

Xgene Pharmaceutical, Inc. is a venture capital-backed company based in an international location. Xgene Pharmaceutical utilizes their proprietary linker technology to create novel, multimodal, conjugated molecules for the treatment of neurological disorders. The Chinese company's focus is on improving the efficacy and tolerability of pain therapeutics by addressing the complexity of any given disease. Healthcare professionals frequently prescribe more than one therapeutic agent, each with a different mode of action, and multi-modal therapy has demonstrated improved outcomes across a range of conditions. Xgene Pharmaceutical provides a link to better therapies. The company was founded in 2015 by Jing Hong Xu and Feng Xu, with Jing Hong Xu serving as the CEO since then.